Prevalence of and Risk Factors for Hepatic Steatosis in Northern Italy
Overview
Affiliations
Background: Although hepatic steatosis is seen with increasing frequency in clinical practice, its prevalence and risk factors are unknown.
Objective: To investigate the prevalence of and risk factors for hepatic steatosis, such as alcohol consumption and obesity.
Design: Cross-sectional, observational study.
Setting: Participants in the Dionysos Study.
Patients: 257 participants assigned to one of four categories (67 controls, 66 obese persons, 69 heavy drinkers, and 55 obese heavy drinkers).
Measurements: Ethanol intake, assessed by a validated questionnaire and expressed as daily (g/d) and lifetime (kg) consumption, and body mass, expressed as body mass index. Biochemical tests of liver and metabolic function and hepatic ultrasonography were done.
Results: The prevalence of steatosis was increased in heavy drinkers (46.4% [95% CI, 34% to 59%]) and obese persons (75.8% [CI, 63% to 85%]) compared with controls (16.4% [CI, 8% to 25%]). Steatosis was found in 94.5% (CI, 85% to 99%) of obese heavy drinkers. Compared with controls, the risk for steatosis was higher by 2.8-fold (CI, 1.4-fold to 7.1-fold) in heavy drinkers, 4.6-fold (CI, 2.5-fold to 11.0-fold) in obese persons, and 5.8-fold (CI, 3.2-fold to 12.3-fold) in persons who were obese and drank heavily. In heavy drinkers, obesity increased the risk for steatosis by twofold (CI, 1.5-fold to 3.0-fold) (P < 0.001), but heavy drinking was associated with only a 1.3-fold (CI, 1.02-fold to 1.6-fold) increase in risk in obese persons (P = 0.0053). Elevated alanine aminotransferase and triglyceride levels are the most reliable markers of steatosis.
Conclusions: Steatosis is frequently encountered in healthy persons and is almost always present in obese persons who drink more than 60 g of alcohol per day. Steatosis is more strongly associated with obesity than with heavy drinking, suggesting a greater role of overweight than alcohol consumption in accumulation of fat in the liver.
Krefting F, Scheib C, Benson S, Holsken S, Placke J, Wedemeyer H Psoriasis (Auckl). 2025; 15:29-44.
PMID: 40046951 PMC: 11881625. DOI: 10.2147/PTT.S502296.
Yang C, Wu J, Yang L, Hu Q, Li L, Yang Y Sci Rep. 2024; 14(1):22385.
PMID: 39333290 PMC: 11436816. DOI: 10.1038/s41598-024-72909-8.
Efficacy of Addiction Pharmacotherapy in Alcohol Use Disorder and Their Effects on Liver Health.
Zhou J, Li J, Pan Q, Ayada I J Clin Transl Hepatol. 2024; 12(8):750-754.
PMID: 39130618 PMC: 11310752. DOI: 10.14218/JCTH.2024.00059.
AkbariRad M, Pezeshki Rad M, Nobakht H, Moodi Ghalibaf A, Firoozi A, Torshizian A BMC Gastroenterol. 2024; 24(1):212.
PMID: 38926664 PMC: 11210030. DOI: 10.1186/s12876-024-03302-y.
Aerts M, Rosseel Z, De Waele E Nutrients. 2024; 16(11).
PMID: 38892517 PMC: 11174485. DOI: 10.3390/nu16111584.